TABLE 1.
(A) Functions | Regulation of vascular permeability | Mechanical barrier and charge barrier | Deen et al., 2001; Kutuzov et al., 2018; Zhu et al., 2018 |
Regulation of vascular tone | Inducing and transmitting the shear stress change signal to the endothelial cells to synthesize and release nitric oxide | Ebong et al., 2014; Yen et al., 2015; Bartosch et al., 2017 | |
Attenuation of leukocyte adhesion | Reducing leukocyte contact with ICAM-1,ICAM-2, and VCAM-1 | Van den Berg et al., 2006; Kim et al., 2013 | |
Attenuation of platelet adhesion | Reducing platelet contact with PECAM-1 | Bell et al., 2017; Lupu et al., 2020 | |
(B) Major shedding enzyme | MMPs | Cleaving core protein backbone of glycocalyx, directly | Endo et al., 2003; Song et al., 2015; Reine et al., 2019; Ali et al., 2019 |
HPSE | Cutting HS | Shteper et al., 2003; Baraz et al., 2006; Qu et al., 2016; Zheng et al., 2016 | |
HAase | Cutting HA | Nieuwdorp et al., 2007; Becker et al., 2015 | |
(C) Protection strategies of glycocalyx | Glucocorticoid | Stabilizing mast cells | Cui et al., 2015; Yu et al., 2019 |
Antithrombin agents | Stabilizing glycocalyx structure by combining with it | Chappell et al., 2009a,b | |
Abumin | Similar to that of antithrombin | Becker et al., 2015; Aldecoa et al., 2020 | |
Etanercept | TNF-α inhibitor | Nieuwdorp et al., 2009 | |
Sulodexide | Inhibiting HPSE and MMPs activities | Mannello and Raffetto, 2011; van Haare et al., 2017 | |
Doxycycline and batimastat | Inhibitors of MMPs | Lipowsky et al., 2011; Lipowsky and Lescanic, 2013 | |
Sevoflurane | Reduce MMPs production | Annecke et al., 2010; Fang et al., 2021 |
ICAM, intercellular adhesion molecules; VCAM, vascular cell adhesion molecule; PECAM, platelet/endothelial cell adhesion molecule; HPSE, heparinase; HAase, hyaluronidase; MMPs, matrix metalloproteinases; TIMPs tissue inhibitor of matrix metalloproteinases; HDAC, histone deacetylase; HA, hyaluronic acid; HS, heparan sulfate.